Asahi Kasei Pharma Corporation

Looking for a EU partner for a licensing agreement

KEY ACTIVITIES Pharmaceutical R&D, Manufacturing, Sales
SECTOR: Pharmaceutical
KEY WORDS: Chronic pain, rheumatoid arthritis, bone/cartilage tissue repair and regeneration
TYPE OF ACTIVITIES Research collaboration

Company Activity Description:

Asahi Kasei Pharma Corporation will perform its open innovation competition program in winter 2018. The company is looking forward to having opportunities for research collaboration or licensing in the chronic pain field.

 

Type of Partnership Sought:

1.Research collaboration
2.License agreement

 

Additional information:

Asahi Kasei Pharma Corporation is looking for partners affiliated with universities, research institutions and small biotech in the area of chronic pain, rheumatoid arthritis and bone/cartilage tissue repair and regeneration.

Wish list:
Chronic Pain
1.1    New drug-target molecules or drug candidates in the field of pain management.
1.2    New and innovative technologies for pain assessment.

Rheumatoid Arthritis
2.1    Drug candidates for rheumatoid arthritis.

Bone/cartilage tissue repair and regeneration
3.1 New drug target for a new therapeutic approach for bone or cartilage repair/regeneration
3.2 A new cell-based assay, animal model, biomarker, or imaging technology which facilitates translation of preclinical findings to clinical outcomes in bone/cartilage regenerative medicine

 Company overview:
Asahi Kasei Pharma believes “locomotive syndrome” to be a serious problem that needs to be urgently addressed in their aging society. For this reason, the company dedicates its research and development efforts toward developing new drugs that help patients worldwide who are suffering from chronic pain, metabolic bone diseases, or rheumatoid arthritis. 

Asahi Kasei Pharma is a leader in the field of these disorders and has thus far developed the synthetic calcitonin derivative Elcitonin®, the human parathyroid hormone preparation Teribone®, and the immunosuppressant Bredinin®. In the future, the company will continue in their efforts to generate a steady flow of new innovative drugs. To achieve this, Asahi Kasei Pharma aims to build a larger pipeline of new drug candidates through collaboration with its research partners and further strengthen our drug development capabilities in the areas of orthopedics and musculoskeletal disorders.

Also see "Call for applicantshttps" closed

Company website